While the world obsesses over AI chatbots, Altoida is quietly building a silent sentinel for your brain. By turning your smartphone into a digital biomarker detector, they're racing to spot Alzheimer's and Parkinson's years before clinical symptoms appear—and they've already secured $16.8M to do it.

"Altoida isn't just tracking brain health—they're quantifying the unquantifiable, turning subtle digital interactions into predictive neurological insights."

The leadership team reads like a neurotech dream team: Marc Jones as CEO, Shawn Fitzgerald heading Quality Management (critical for FDA pathways), Robbert Harms leading Data Science, Nivaldo Diaz overseeing Software Product Development, and Jodi McGroarty managing Customer Success. This isn't a consumer app startup—it's a clinical tool disguised as a digital experience, with the regulatory and operational rigor to match.

• Digital biomarker platform that detects neurodegenerative diseases 6-10 years before clinical diagnosis
• 120+ passive and active measurements from standard smartphone interactions
• FDA-cleared for clinical use, bridging the gap between consumer tech and medical device
• Strong organic search strategy targeting high-intent medical queries
• 67-person team with deep expertise in neuroscience, data science, and regulatory affairs